A Study of LY3502970 in Participants With Impaired and Normal Liver Function
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream
and how long it takes the body to eliminate it in participants with mild, moderate and severe
impaired liver function compared to participants with normal liver function. The safety and
tolerability of LY3502970 will also be evaluated. The study may last up to 6 weeks for each
participant including the screening period.